bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
Authors: O'Brien Katie M. , Cole Stephen R. , Tse Chiu-Kit , Perou Charles M. , Carey Lisa A. , Foulkes William D. , Dressler Lynn G. , Geradts Joseph , Millikan Robert C.
Published: April 2023

PDF file - 22K
Supplementary Tables 1-3 from Role of Smac in Determining the Chemotherapeutic Response of Esophageal Squamous Cell Carcinoma
Authors: Xu Yang , Zhou Lanping , Huang Jing , Liu Fang , Yu Jian , Zhan Qimin , Zhang Lin , Zhao Xiaohang
Published: April 2023

PDF file - 155K
Supplementary Figure 2 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Authors: Santel Ansgar , Aleku Manuela , Röder Nadine , Möpert Kristin , Durieux Birgit , Janke Oliver , Keil Oliver , Endruschat Jens , Dames Sibylle , Lange Christian , Eisermann Mona , Löffler Kathrin , Fechtner Melanie , Fisch Gerald , Vank Christiane , Schaeper Ute , Giese Klaus , Kaufmann Jörg
Published: April 2023

PDF file - 477K
Supplementary Figure 1 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Authors: Santel Ansgar , Aleku Manuela , Röder Nadine , Möpert Kristin , Durieux Birgit , Janke Oliver , Keil Oliver , Endruschat Jens , Dames Sibylle , Lange Christian , Eisermann Mona , Löffler Kathrin , Fechtner Melanie , Fisch Gerald , Vank Christiane , Schaeper Ute , Giese Klaus , Kaufmann Jörg
Published: April 2023

PDF file - 485K
Supplementary Data from A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer
Authors: Ahn Richard W. , Chen Feng , Chen Haimei , Stern Stephan T. , Clogston Jeffrey D. , Patri Anil K. , Raja Meera R. , Swindell Elden P. , Parimi Vamsi , Cryns Vincent L. , O'Halloran Thomas V.
Published: April 2023

Supplementary Data from A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer
Appendix (1-4) from KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
Authors: Blank Patricia R. , Moch Holger , Szucs Thomas D. , Schwenkglenks Matthias
Published: April 2023

Appendix 1. Medical resource use and cost data Appendix 2. Results of the deterministic sensitivity analysis addressing the impact of parameter uncertainty Appendix 3. Deterministic sensitivity analysis of incremental costs (EUR) per QALY gained (ICER) (Scenario analysis) Appendix 4. Incremental cost-effectiveness scatterplot of KRAS and BRAF testing versus no certuximab
Supplementary Figures S1-S2 from Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells
Authors: Xu Hai , Stabile Laura P. , Gubish Christopher T. , Gooding William E. , Grandis Jennifer R. , Siegfried Jill M.
Published: April 2023

Supplementary Figures S1-S2 from Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells
Supplementary Table S2 from Involvement of the TGF-β and β-Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer
Authors: Noordhuis Maartje G. , Fehrmann Rudolf S.N. , Wisman G. Bea A. , Nijhuis Esther R. , van Zanden Jelmer J. , Moerland Perry D. , Ver Loren van Themaat Emiel , Volders Haukeline H. , Kok Mirjam , ten Hoor Klaske A. , Hollema Harry , de Vries Elisabeth G.E. , de Bock Geertruida H. , van der Zee Ate G.J. , Schuuring Ed
Published: April 2023

Supplementary Table S2 from Involvement of the TGF-β and β-Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer
Supplementary Figure 4 from Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
Authors: Allen Elizabeth , Walters Ian B. , Hanahan Douglas
Published: April 2023

PDF file - 158K
Supplementary Methods from The Prognostic Significance of Various 13q14 Deletions in Chronic Lymphocytic Leukemia
Authors: Ouillette Peter , Collins Roxane , Shakhan Sajid , Li Jinghui , Li Cheng , Shedden Kerby , Malek Sami N.
Published: April 2023

PDF file - 59KB
Supplementary Figure and Table Legends from The Prognostic Significance of Various 13q14 Deletions in Chronic Lymphocytic Leukemia
Authors: Ouillette Peter , Collins Roxane , Shakhan Sajid , Li Jinghui , Li Cheng , Shedden Kerby , Malek Sami N.
Published: April 2023

PDF file - 58KB
Supplementary Figure 4 from Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5
Authors: Zhu Yinghua , Yu Fengyan , Jiao Yu , Feng Juan , Tang Wei , Yao Herui , Gong Chang , Chen Jianing , Su Fengxi , Zhang Yan , Song Erwei
Published: April 2023

PDF file - 631K
Supplementary Tables 1 - 4 from The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization
Authors: Sekhar Konjeti R. , Reddy Yerramreddy Thirupathi , Reddy Penthala Narsimha , Crooks Peter A. , Venkateswaran Amudhan , McDonald William Hayes , Geng Ling , Sasi Soumya , Van Der Waal Robert P. , Roti Joseph L. Roti , Salleng Kenneth J. , Rachakonda Girish , Freeman Michael L.
Published: April 2023

PDF file - 71KB
Supplementary Figures 1 - 7 from The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization
Authors: Sekhar Konjeti R. , Reddy Yerramreddy Thirupathi , Reddy Penthala Narsimha , Crooks Peter A. , Venkateswaran Amudhan , McDonald William Hayes , Geng Ling , Sasi Soumya , Van Der Waal Robert P. , Roti Joseph L. Roti , Salleng Kenneth J. , Rachakonda Girish , Freeman Michael L.
Published: April 2023

PDF file - 173KB
Supplementary Figure 1 from Novel Phosphoinositide 3-Kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo
Authors: Chang Kwang-Yu , Tsai Shan-Yin , Wu Ching-Ming , Yen Chia-Jui , Chuang Bin-Fay , Chang Jang-Yang
Published: April 2023

PDF file - 757KB, Effect of the cell growth and the intracellular signals by BGT226. (A) Growth inhibitory effect of BGT226, rapamycin and LY294002. FaDu and OECM1 cells were treated with each compound in the identical concentration-dependent manner. The result was plotted (X axis, logarithm scale of concentration; y axis, ratio). (B) Effect of BGT226 and the other PI3K/mTOR targeting agents in OECM1. In the left panel, cells were treated with BGT226 120 nM or LY294002 2μM in a time-dependent manner. In the right panel, cells were treated with various PI3K/mTOR targeting agents for 30 min before whole cell lysate collection (G, BGT226 120 nM; K, BKM120 2μM; Rad, RAD001, 0.5 or 2 nM; L, LY294002 2μM; Rapa, rapamycin 100 or 200 nM; C, control).
Supplementary Figure 4 from GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Authors: Wallin Jeffrey J. , Guan Jane , Prior Wei Wei , Lee Leslie B. , Berry Leanne , Belmont Lisa D. , Koeppen Hartmut , Belvin Marcia , Friedman Lori S. , Sampath Deepak
Published: April 2023

PDF file, 148KB, Cell Cycle Analysis of MCF7-neo/HER2 Cells After Treatment with GDC-0941, Docetaxel (DTX) or the Combination of Both Drugs.
Supplementary Tables 6-7 from Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy
Authors: Tonelli Roberto , McIntyre Alan , Camerin Consuelo , Walters Zoë S. , Di Leo Korinne , Selfe Joanna , Purgato Stefania , Missiaglia Edoardo , Tortori Andrea , Renshaw Jane , Astolfi Annalisa , Taylor Kathryn R. , Serravalle Salvatore , Bishop Ryan , Nanni Cristina , Valentijn Linda J. , Faccini Andrea , Leuschner Ivo , Formica Serena , Reis-Filho Jorge S. , Ambrosini Valentina , Thway Khin , Franzoni Monica , Summersgill Brenda , Marchelli Rosangela , Hrelia Patrizia , Cantelli-Forti Giorgio , Fanti Stefano , Corradini Roberto , Pession Andrea , Shipley Janet
Published: April 2023

PDF file - 72K
Supplementary Figure 2 from GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Authors: Wallin Jeffrey J. , Guan Jane , Prior Wei Wei , Lee Leslie B. , Berry Leanne , Belmont Lisa D. , Koeppen Hartmut , Belvin Marcia , Friedman Lori S. , Sampath Deepak
Published: April 2023

PDF file, 137KB, Time-Lapse Photomicrographs of HCC-1954 Breast Cancer Cells Treated with GDC-0941, Docetaxel (DTX) or the Combination of Both Drugs.
Supplementary Methods, Table 1, Figure Legend 1 from A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
Authors: Shanmugam Rajasubramaniam , Gade Padmaja , Wilson-Weekes Annique , Sayar Hamid , Suvannasankha Attaya , Goswami Chirayu , Li Lang , Gupta Sushil , Cardoso Angelo A. , Al Baghdadi Tareq , Sargent Katie J. , Cripe Larry D. , Kalvakolanu Dhananjaya V. , Boswell H. Scott
Published: April 2023

PDF file - 112K
Supplementary Figure 4 from Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy
Authors: Tonelli Roberto , McIntyre Alan , Camerin Consuelo , Walters Zoë S. , Di Leo Korinne , Selfe Joanna , Purgato Stefania , Missiaglia Edoardo , Tortori Andrea , Renshaw Jane , Astolfi Annalisa , Taylor Kathryn R. , Serravalle Salvatore , Bishop Ryan , Nanni Cristina , Valentijn Linda J. , Faccini Andrea , Leuschner Ivo , Formica Serena , Reis-Filho Jorge S. , Ambrosini Valentina , Thway Khin , Franzoni Monica , Summersgill Brenda , Marchelli Rosangela , Hrelia Patrizia , Cantelli-Forti Giorgio , Fanti Stefano , Corradini Roberto , Pession Andrea , Shipley Janet
Published: April 2023

PDF file - 347K
CCR Translation for This Article from Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy
Authors: Tonelli Roberto , McIntyre Alan , Camerin Consuelo , Walters Zoë S. , Di Leo Korinne , Selfe Joanna , Purgato Stefania , Missiaglia Edoardo , Tortori Andrea , Renshaw Jane , Astolfi Annalisa , Taylor Kathryn R. , Serravalle Salvatore , Bishop Ryan , Nanni Cristina , Valentijn Linda J. , Faccini Andrea , Leuschner Ivo , Formica Serena , Reis-Filho Jorge S. , Ambrosini Valentina , Thway Khin , Franzoni Monica , Summersgill Brenda , Marchelli Rosangela , Hrelia Patrizia , Cantelli-Forti Giorgio , Fanti Stefano , Corradini Roberto , Pession Andrea , Shipley Janet
Published: April 2023

CCR Translation for This Article from Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy
Supplementary Figure 2 from L1 Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non–Small Cell Lung Cancer
Authors: Hai Josephine , Zhu Chang-Qi , Bandarchi Bizhan , Wang Yu-Hui , Navab Roya , Shepherd Frances A. , Jurisica Igor , Tsao Ming-Sound
Published: April 2023

PDF file - 220K
Supplementary Table 1 from Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Gerger Armin , El-Khoueiry Anthony , Zhang Wu , Yang Dongyun , Singh Harpreet , Bohanes Pierre , Ning Yan , Winder Thomas , LaBonte Melissa J. , Wilson Peter M. , Benhaim Leonor , Paez David , El-Khoueiry Rita , Absenger Gudrun , Lenz Heinz-Josef
Published: April 2023

PDF file - 71K
Supplementary Figures 1-7, Tables 1-4 from Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Authors: Hurvitz Sara A. , Betting David J. , Stern Howard M. , Quinaux Emmanuel , Stinson Jeremy , Seshagiri Somasekar , Zhao Ying , Buyse Marc , Mackey John , Driga Adrian , Damaraju Sambasivarao , Sliwkowski Mark X. , Robert Nicholas J. , Valero Vicente , Crown John , Falkson Carla , Brufsky Adam , Pienkowski Tadeusz , Eiermann Wolfgang , Martin Miguel , Bee Valerie , Marathe Omkar , Slamon Dennis J. , Timmerman John M.
Published: April 2023

PDF file - 507K, Supplemental Table 1A: PCR and Sanger Sequencing Primers Supplemental Table 1B: PCR and Sequenom Genotyping Primers Supplemental Figure 1. Kaplan-Meier estimates of disease free survival for BCIRG 006 study, entire population, third planned analysis. (N=3222) Supplemental Table 2. Patient Characteristics: Genotyped vs. Non-genotyped Supplemental Figure 2. Kaplan-Meier estimates of disease free survival in subset of patients enrolled in BCIRG006 (third planned analysis) who were genotyped for this study (N=1,286) Supplemental Figure 3. Kaplan-Meier estimates of disease free survival in subset of patients enrolled in BCIRG006 (third planned analysis) who were genotyped for this study with stratification for major prognostic factors Supplemental Table 3. Patients Characteristics by Genotype (Advanced Disease Cohort) Supplemental Table 4. Genotype and Allele Frequencies of the FCGR2A and FCGR3A Polymorphisms Supplemental Figure 4. Kaplan-Meier estimates of disease free survival in trastuzumab treated patients within the adjuvant cohort according to FcGammaR polymorphisms, broken down by treatment arm Supplemental Figure 5. Kaplan-Meier estimates of disease free survival in patients treated with chemotherapy alone (no trastuzumab) in the adjuvant cohort according to FcGammaR polymorphisms, broken down by treatment arm. Supplemental Figure 6. Kaplan-Meier estimates of overall survival (OS) in trastuzumab treated patients within the adjuvant cohort according to FcGammaR polymorphisms. Supplemental Figure 7. Kaplan-Meier estimates of progression free survival (PFS) in trastuzumab treated patients within the advanced disease cohort according to FcGammaR polymorphisms.
Supplementary Figure 6 from Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma
Authors: Kubo Takafumi , Toyooka Shinichi , Tsukuda Kazunori , Sakaguchi Masakiyo , Fukazawa Takuya , Soh Junichi , Asano Hiroaki , Ueno Tsuyoshi , Muraoka Takayuki , Yamamoto Hiromasa , Nasu Yasutomo , Kishimoto Takumi , Pass Harvey I. , Matsui Hideki , Huh Nam-ho , Miyoshi Shinichiro
Published: April 2023

PDF file - 247K, The effect of the silencing of c-MET protein by siRNA on MPM cell lines. siRNAs targeting c-MET were designed with siDirect online software system (http://www.rnai.co.jp/e_index.html). siRNA sequences targeting two different regions of c-MET are as follows (sense and antisense, respectively): si-c-MET-1 (5'-CAUUGCAUUCGAUAUCAGUGA-3' and 5'-ACUGAUAUCGAAUGCAAUGGA-3') and si-c-Met-2 (5'-CAUGUCAACAUCGCUCUAAUU-3' and 5'-UUAGAGCGAUGUUGACAUGCC-3'). Cells were transfected with 20 nM of siRNA using LipofectamineTM RNAiMAX (Invitrogen) according to the manufacturer's protocol. Control cells were treated with RNAiMAX alone or with scramble. Cell viability after siRNA introduction was determined by a MTS assay.
Supplementary Figure 2 from Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
Authors: Lazova Rossitza , Camp Robert L. , Klump Vincent , Siddiqui Summar F. , Amaravadi Ravi K. , Pawelek John M.
Published: April 2023

PDF file - 97K
Supplementary Figure 1 from Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
Authors: Lazova Rossitza , Camp Robert L. , Klump Vincent , Siddiqui Summar F. , Amaravadi Ravi K. , Pawelek John M.
Published: April 2023

PDF file - 4.5MB
Supplementary Table 2 from Colorectal Cancers with Microsatellite Instability Display Unique miRNA Profiles
Authors: Balaguer Francesc , Moreira Leticia , Lozano Juan Jose , Link Alexander , Ramirez Georgina , Shen Yan , Cuatrecasas Miriam , Arnold Mildred , Meltzer Stephen J. , Syngal Sapna , Stoffel Elena , Jover Rodrigo , Llor Xavier , Castells Antoni , Boland C. Richard , Gironella Meritxell , Goel Ajay
Published: April 2023

PDF file - 54K
Supplementary Table 1 from Colorectal Cancers with Microsatellite Instability Display Unique miRNA Profiles
Authors: Balaguer Francesc , Moreira Leticia , Lozano Juan Jose , Link Alexander , Ramirez Georgina , Shen Yan , Cuatrecasas Miriam , Arnold Mildred , Meltzer Stephen J. , Syngal Sapna , Stoffel Elena , Jover Rodrigo , Llor Xavier , Castells Antoni , Boland C. Richard , Gironella Meritxell , Goel Ajay
Published: April 2023

XLS file - 451K
Supplementary Figure 3 from Upregulation of Notch2 and Six1 Is Associated with Progression of Early-Stage Lung Adenocarcinoma and a More Aggressive Phenotype at Advanced Stages
Authors: Mimae Takahiro , Okada Morihito , Hagiyama Man , Miyata Yoshihiro , Tsutani Yasuhiro , Inoue Takao , Murakami Yoshinori , Ito Akihiko
Published: April 2023

PDF file - 164K
Supplementary Figure 2 from Inhibition of the Notch-Hey1 Axis Blocks Embryonal Rhabdomyosarcoma Tumorigenesis
Authors: Belyea Brian C. , Naini Sarasija , Bentley Rex C. , Linardic Corinne M.
Published: April 2023

PDF file - 1MB
Supplementary Figure 5 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
Authors: Fraser Michael , Zhao Helen , Luoto Kaisa R. , Lundin Cecilia , Coackley Carla , Chan Norman , Joshua Anthony M. , Bismar Tarek A. , Evans Andrew , Helleday Thomas , Bristow Robert G.
Published: April 2023

PDF file - 185K
Supplementary Table 4 from Expression of NLRR3 Orphan Receptor Gene Is Negatively Regulated by MYCN and Miz-1, and Its Downregulation Is Associated with Unfavorable Outcome in Neuroblastoma
Authors: Akter Jesmin , Takatori Atsushi , Hossain Md. Shamim , Ozaki Toshinori , Nakazawa Atsuko , Ohira Miki , Suenaga Yusuke , Nakagawara Akira
Published: April 2023

PDF file - 45KB
Supplementary Figure 5 from Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Authors: Landreville Solange , Agapova Olga A. , Matatall Katie A. , Kneass Zachary T. , Onken Michael D. , Lee Ryan S. , Bowcock Anne M. , Harbour J. William
Published: April 2023

PDF file - 2.4MB
Supplementary Table 2 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Authors: Punnoose Elizabeth A. , Atwal Siminder , Liu Weiqun , Raja Rajiv , Fine Bernard M. , Hughes Brett G.M. , Hicks Rodney J. , Hampton Garret M. , Amler Lukas C. , Pirzkall Andrea , Lackner Mark R.
Published: April 2023

PDF file - 181K
CCR Translation for This Article from Bayesian Hierarchical Changepoint Methods in Modeling the Tumor Growth Profiles in Xenograft Experiments
Authors: Zhao Lili , Morgan Meredith A. , Parsels Leslie A. , Maybaum Jonathan , Lawrence Theodore S. , Normolle Daniel
Published: April 2023

CCR Translation for This Article from Bayesian Hierarchical Changepoint Methods in Modeling the Tumor Growth Profiles in Xenograft Experiments
Supplementary Tables 1-7 from Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non–Small-Cell Lung Cancer Patients
Authors: Xie Yang , Xiao Guanghua , Coombes Kevin R. , Behrens Carmen , Solis Luisa M. , Raso Gabriela , Girard Luc , Erickson Heidi S. , Roth Jack , Heymach John V. , Moran Cesar , Danenberg Kathy , Minna John D. , Wistuba Ignacio I.
Published: April 2023

PDF file - 153K
Supplementary Table 9 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Authors: Jamieson Nigel B. , Morran Douglas C. , Morton Jennifer P. , Ali Asif , Dickson Euan J. , Carter C. Ross , Sansom Owen J. , Evans T.R. Jeffry , McKay Colin J. , Oien Karin A.
Published: April 2023

XLS file - 168K, A. Combination of predicted targets for miRNAs associated with favourable prognosis (miR-29c, miR-30d, miR-34a). B. Combination of predicted targets for miRNAs associated with poor prognosis (miR-21, miR-221, miR-224).
Supplementary Table 2 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Authors: Jamieson Nigel B. , Morran Douglas C. , Morton Jennifer P. , Ali Asif , Dickson Euan J. , Carter C. Ross , Sansom Owen J. , Evans T.R. Jeffry , McKay Colin J. , Oien Karin A.
Published: April 2023

XLS file - 47K, Conventional clinicopathological factors in PDAC cohort (n = 48) associated with survival following resection based on multivariate analysis.
Supplementary Tables 1-7 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
Authors: Manola Judith , Royston Patrick , Elson Paul , McCormack Jennifer Bacik , Mazumdar Madhu , Négrier Sylvie , Escudier Bernard , Eisen Tim , Dutcher Janice , Atkins Michael , Heng Daniel Y.C. , Choueiri Toni K. , Motzer Robert , Bukowski Ronald
Published: April 2023

PDF file - 108K
Supplementary Figure 3 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Authors: Jamieson Nigel B. , Morran Douglas C. , Morton Jennifer P. , Ali Asif , Dickson Euan J. , Carter C. Ross , Sansom Owen J. , Evans T.R. Jeffry , McKay Colin J. , Oien Karin A.
Published: April 2023

PDF file - 648K, Investigation of gene targets of miR-21 and miR-34a in human PDAC. A - C) Correlation plots of RT-PCR miR-21 expression (relative expression) versus cytoplasmic Bcl-2 protein expression (Spearman's � correlation coefficient = 0.411, P = 0.003), cytoplasmic maspin expression (� = 0.653, P < 0.001), and cytoplasmic PTEN expression (� = 0.43, P = 0.004) (n = 43). IHC assessed using a semi-continuous histoscore. D) Kaplan-Meier analysis illustrating that patients with low PTEN have poorer outcome (n = 38, 13.0 months) compared to those with medium PTEN expression (n = 41, 16.7 months) and high PTEN expression (n = 38, 26.6 months) following pancreaticoduodenectomy (Log-Rank test, P = 0.01). The cohort was divided into tertiles according to the PTEN histoscore. E - F) Correlation plots of miR-34a expression with cytoplasmic Bcl-2 protein expression (� = -0.496, P = 0.001) and nuclear cyclin D1 protein expression (� = -0.293, P = 0.043) (n = 43). G) Correlation of nuclear p53 protein expression with miR-34a expression (� = 0.392, P = 0.01) (n = 43).
Supplementary Figure 1 from Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Authors: Wilmott James S. , Long Georgina V. , Howle Julie R. , Haydu Lauren E. , Sharma Raghwa N. , Thompson John F. , Kefford Richard F. , Hersey Peter , Scolyer Richard A.
Published: April 2023

PDF file - 381K
CCR Translation for This Article from Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Authors: Wilmott James S. , Long Georgina V. , Howle Julie R. , Haydu Lauren E. , Sharma Raghwa N. , Thompson John F. , Kefford Richard F. , Hersey Peter , Scolyer Richard A.
Published: April 2023

CCR Translation for This Article from Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Supplementary Figure Legends from Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
Authors: Fiskus Warren , Verstovsek Srdan , Manshouri Taghi , Rao Rekha , Balusu Ramesh , Venkannagari Sreedhar , Rao Nalabothula Narasimha , Ha Kyungsoo , Smith Jacqueline E. , Hembruff Stacey L. , Abhyankar Sunil , McGuirk Joseph , Bhalla Kapil N.
Published: April 2023

PDF file (68KB)
Supplementary Figure 1D from Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
Authors: Wheler Jennifer , Tsimberidou Apostolia M. , Hong David , Naing Aung , Falchook Gerald , Piha-Paul Sarina , Fu Siqing , Moulder Stacy , Stephen Bettzy , Wen Sijin , Kurzrock Razelle
Published: April 2023

PDF file, 95KB, Kaplan - Meier survival curves by ECOG performance status (0 versus 1+) (n=1,164 patients for whom ECOG performance status was available). Median survival is 13.8 months (95% CI: 11.6 - 17.1) for ECOG performance status=0, and 8.3 months (95% CI: 7.7 - 9.5) for ECOG performance status ≥1 (Log-rank p-value <0.0001).
Supplementary Figures 1 - 8 from Lyn Kinase Mediates Cell Motility and Tumor Growth in EGFRvIII-Expressing Head and Neck Cancer
Authors: Wheeler Sarah E. , Morariu Elena M. , Bednash Joseph S. , Otte Charlton G. , Seethala Raja R. , Chiosea Simion I. , Grandis Jennifer R.
Published: April 2023

PDF file, 1038KB, S1: Dasatinib treatment decreases migration and invasion in EGFRvIII expressing HNSCC. S2:STAT3 expression in dasatinib and Lyn siRNA treated HNSCC cells. S3: Dasatinib inhibits tumor growth in EGFRvIII expressing xenografts. S4: Increased Lyn phosphorylation in EGFRvIII-expressing HNSCC compared to vector-control cells. S5: Increase in Lyn phosphorylation in three separate clones of HNSCC cell lines Cal33. S6: Lyn siRNA specificity. S7: Knockdown of Lyn inhibits EGFRvIII-mediated HNSCC migration and invasion. S8: Knockdown of Lyn with a second siRNA confirms inhibition of EGFRvIII-mediated HNSCC migration and invasion.
Supplementary Table 2 from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration
Authors: Keutgen Xavier M. , Filicori Filippo , Crowley Michael J. , Wang Yongchun , Scognamiglio Theresa , Hoda Rana , Buitrago Daniel , Cooper David , Zeiger Martha A. , Zarnegar Rasa , Elemento Olivier , Fahey Thomas J.
Published: April 2023

PDF file - 78K
Supplementary Figure 2 from iASPP and Chemoresistance in Ovarian Cancers: Effects on Paclitaxel-Mediated Mitotic Catastrophe
Authors: Jiang LiLi , Siu Michelle K.Y. , Wong Oscar G.W. , Tam Kai-Fai , Lu Xin , Lam Eric W-F. , Ngan Hextan Y.S. , Le Xiao-Feng , Wong Esther S.Y. , Monteiro Lara J. , Chan Hoi-Yan , Cheung Annie N.Y.
Published: April 2023

PDF file - 2.7MB, Supplementary Figure 2. Consistent results were found with iASPP knockdown demonstrating that abrogating iASPP could enhance paclitaxel-mediated mitotic catastrophe in both ovarian cancer cell lines (control, vector-transfected control cells; arrow, apoptosis; arrowhead, mitotic catastrophe).
Supplementary Table 3 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 114K
Supplementary Figure 1 from Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer
Authors: Kondo Shunsuke , Iwata Satoshi , Yamada Taketo , Inoue Yusuke , Ichihara Hiromi , Kichikawa Yoshiko , Katayose Tomoki , Souta-Kuribara Akiko , Yamazaki Hiroto , Hosono Osamu , Kawasaki Hiroshi , Tanaka Hirotoshi , Hayashi Yuichiro , Sakamoto Michiie , Kamiya Kazunori , Dang Nam H. , Morimoto Chikao
Published: April 2023

PDF file - 85K, Evaluation and selection of siRNA for NEDD9
Supplementary Figure 4 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Authors: Rosa Roberta , Melisi Davide , Damiano Vincenzo , Bianco Roberto , Garofalo Sonia , Gelardi Teresa , Agrawal Sudhir , Di Nicolantonio Federica , Scarpa Aldo , Bardelli Alberto , Tortora Giampaolo
Published: April 2023

PDF file - 204KB
Supplementary Table 1 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 73K
Supplementary Figure 3 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Authors: Rosa Roberta , Melisi Davide , Damiano Vincenzo , Bianco Roberto , Garofalo Sonia , Gelardi Teresa , Agrawal Sudhir , Di Nicolantonio Federica , Scarpa Aldo , Bardelli Alberto , Tortora Giampaolo
Published: April 2023

PDF file - 555KB
Supplementary Table 4 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
Authors: Agnelli Luca , Forcato Mattia , Ferrari Francesco , Tuana Giacomo , Todoerti Katia , Walker Brian A. , Morgan Gareth J. , Lombardi Luigia , Bicciato Silvio , Neri Antonino
Published: April 2023

XLS file - 52K
Supplementary Figure 3 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
Authors: Karapanagiotou Eleni M. , Roulstone Victoria , Twigger Katie , Ball Mercel , Tanay MaryAnne , Nutting Chris , Newbold Kate , Gore Martin E. , Larkin James , Syrigos Konstantinos N. , Coffey Matt , Thompson Brad , Mettinger Karl , Vile Richard G. , Pandha Hardev S. , Hall Geoff D. , Melcher Alan A. , Chester John , Harrington Kevin J.
Published: April 2023

PDF file - 267K
Supplementary Figure 1 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
Authors: Karapanagiotou Eleni M. , Roulstone Victoria , Twigger Katie , Ball Mercel , Tanay MaryAnne , Nutting Chris , Newbold Kate , Gore Martin E. , Larkin James , Syrigos Konstantinos N. , Coffey Matt , Thompson Brad , Mettinger Karl , Vile Richard G. , Pandha Hardev S. , Hall Geoff D. , Melcher Alan A. , Chester John , Harrington Kevin J.
Published: April 2023

PDF file - 48K
Data Supplement from Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
Authors: Blumenschein George R. , Saintigny Pierre , Liu Suyu , Kim Edward S. , Tsao Anne S. , Herbst Roy S. , Alden Christine , Lee J. Jack , Tang Ximing , Stewart David J. , Kies Merrill S. , Fossella Frank V. , Tran Hai T. , Mao L. , Hicks Marshall E. , Erasmus Jeremy , Gupta Sanjay , Girard Luc , Peyton Michael , Diao Lixia , Wang Jing , Davis Suzanne E. , Minna John D. , Wistuba Ignacio , Hong Waun K. , Heymach John V. , Lippman Scott M.
Published: April 2023

Supplementary Table 2. Genes included in the sorafenib sensitivity signature.
Supplementary Methods from Improved Statistical Modeling of Tumor Growth and Treatment Effect in Preclinical Animal Studies with Highly Heterogeneous Responses In Vivo
Authors: Laajala Teemu D. , Corander Jukka , Saarinen Niina M. , Mäkelä Katja , Savolainen Saija , Suominen Mari I. , Alhoniemi Esa , Mäkelä Sari , Poutanen Matti , Aittokallio Tero
Published: April 2023

PDF file, 933K, Full model formulation and details of its estimation, inference and validation.
Supplementary Tables 3 - 6 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
Authors: Walton Mike I. , Eve Paul D. , Hayes Angela , Valenti Melanie R. , De Haven Brandon Alexis K. , Box Gary , Hallsworth Albert , Smith Elizabeth L. , Boxall Kathy J. , Lainchbury Michael , Matthews Thomas P. , Jamin Yann , Robinson Simon P. , Aherne G. Wynne , Reader John C. , Chesler Louis , Raynaud Florence I. , Eccles Suzanne A. , Collins Ian , Garrett Michelle D.
Published: April 2023

PDF file, 79K, Supplementary Table 3 - Mouse body weights for data in Figure 4A Body Weights expressed as a percentage of the weight on day 0 for mice bearing HT29 xenografts and treated with gemcitabine (100mg/kg iv), CCT244747 (75mg/kg po) or the combination. Values are mean�SE, n= 3 to 6. Supplementary Table 4 - Mouse body weights for data in Figure 4C Body Weights expressed as a percentage of the weight on day 0 for mice bearing HT29 xenografts and treated with irinotecan (25mg/kg ip), CCT244747 (150mg/kg po) or the combination. Values are mean�SE, n= 3 to 6. Supplementary Table 5 - Mouse body weights for data in Figure 4D Body Weights expressed as a percentage of the weight on day 0 for mice bearing Calu6 xenografts and treated with gemcitabine (100 mg/kg iv), CCT244747 (75mg/kg po) or the combination. Values are mean�SE, n= 3 to 6. Supplementary Table 6 - Mouse body weights for data in Supplementary Table 2 Body Weights expressed as a percentage of the weight on day 0 for mice bearing SW620 xenografts and treated with gemcitabine (100 mg/kg iv), CCT244747 (75mg/kg po) or the combination. Values are mean�SE, n= 3 to 6.
Supplementary Figure 1 from The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma
Authors: Miyazaki Yasumasa , Kosaka Takeo , Mikami Shuji , Kikuchi Eiji , Tanaka Nobuyuki , Maeda Takahiro , Ishida Masaru , Miyajima Akira , Nakagawa Ken , Okada Yasunori , Sato Yasufumi , Oya Mototsugu
Published: April 2023

PDF file - 169K, Supplementary Figure 1A. Kaplan-Meier recurrence-free survival of the 171 patients after surgery for UTUC stratified according to the cut-off level of MVD 70/mm2: High level of MVD was not an independent predictor of tumor recurrence (P = 0.216). Supplementary Figure 1B. Kaplan-Meier cancer-specific survival of the 171 patients after surgery for UTUC stratified according to the cut-off level of MVD 70/mm2: High level of MVD was not an independent predictor of cancer-specific survival (P = 0.473). Supplementary Figure 1C. Kaplan-Meier recurrence-free survival of the 171 patients after surgery for UTUC stratified according to the cut-off level of MVD 80/mm2: High level of MVD was not an independent predictor of tumor recurrence (P = 0.092). Supplementary Figure 1D. Kaplan-Meier cancer-specific survival of the 171 patients after surgery for UTUC stratified according to the cut-off level of MVD 80/mm2: High level of MVD was not an independent predictor of cancer-specific survival (P = 0.345). Supplementary Figure 1E. Kaplan-Meier recurrence-free survival of the 171 patients after surgery for UTUC stratified according to the cut-off level of VASH1 density 40/mm2: High level of VASH1 density was an independent predictor of tumor recurrence (P = 0.017). Supplementary Figure 1F. Kaplan-Meier cancer-specific survival of the 171 patients after surgery for UTUC stratified according to the cut-off level of VASH1 density 40/mm2: High level of VASH1 density was an independent predictor of cancer-specific survival (P = 0.042). Supplementary Figure 1G. Kaplan-Meier recurrence-free survival of the 171 patients after surgery for UTUC stratified according to the cut-off level of VASH1 density 50/mm2: High level of VASH1 density was an independent predictor of tumor recurrence (P = 0.005). Supplementary Figure 1H. Kaplan-Meier cancer-specific survival of the 171 patients after surgery for UTUC stratified according to the cut-off level of VASH1 density 50/mm2. High level of VASH1 density was an independent predictor of cancer-specific survival (P = 0.027).
Supplementary Table 1 from Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Authors: Arcila Maria E. , Chaft Jamie E. , Nafa Khedoudja , Roy-Chowdhuri Sinchita , Lau Christopher , Zaidinski Michael , Paik Paul K. , Zakowski Maureen F. , Kris Mark G. , Ladanyi Marc
Published: April 2023

PDF file, 76K, Comprehensive list of mutations tested by mass spectrometry (Sequenom).
Supplementary Figure 1 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
Authors: Troiani Teresa , Martinelli Erika , Napolitano Stefania , Vitagliano Donata , Ciuffreda Loreta Pia , Costantino Sara , Morgillo Floriana , Capasso Anna , Sforza Vincenzo , Nappi Anna , De Palma Raffaele , D'Aiuto Elena , Berrino Liberato , Bianco Roberto , Ciardiello Fortunato
Published: April 2023

PDF file 1732K, Development and characterization of cetuximab-resistant SW48 (SW48-CR) colon cancer cells
Supplementary Table 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Authors: Smith Neil R. , Baker Dawn , Farren Matthew , Pommier Aurelien , Swann Ruth , Wang Xin , Mistry Sunita , McDaid Karen , Kendrew Jane , Womack Chris , Wedge Stephen R. , Barry Simon T.
Published: April 2023

PDF file - 90K, TaqMan Fluidigm probe sets.
Supplementary Table 6 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 54K, Top 20 Gene Ontologies Modulated by DZNep in MES1 and H28 Cells.
Supplementary Table 2 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 62K, Demographic Data Pertaining to the Patients from whom NCI-SB-MES 1-4 lines Were Established.
Supplementary Figure 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Authors: Smith Neil R. , Baker Dawn , Farren Matthew , Pommier Aurelien , Swann Ruth , Wang Xin , Mistry Sunita , McDaid Karen , Kendrew Jane , Womack Chris , Wedge Stephen R. , Barry Simon T.
Published: April 2023

PDF file - 121K, Intra-sample distribution of the two phenotypes within diagnostic samples and concordance with the phenotype classifications for matched TMA cores.
Supplementary Figure 5 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 102K, Effects of DZNep treatment on cultured mesothelioma cell lines relative to normal mesothelia cells. Pyrosequencing analysis of NBL2 DNA repeat in normal mesothelia (LP9) and MPM cell lines cultured in the presence or absence of DZNep.
Supplementary Figure 2 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 245K, EZH2 expression in tumors correlates with cell line expression.
Supplementary Figure 2 from Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Authors: Malouf Gabriel G. , Monzon Federico A. , Couturier Jérôme , Molinié Vincent , Escudier Bernard , Camparo Philippe , Su Xiaoping , Yao Hui , Tamboli Pheroze , Lopez-Terrada Dolores , Picken Maria , Garcia Marileila , Multani Asha S. , Pathak Sen , Wood Christopher G. , Tannir Nizar M.
Published: April 2023

PDF file - 166K, Supplementary Figure 2. A, virtual karyotyping of the UOK109 cell line shows the following copy number alterations: +2, +5q,+7,-8p,+8q,-9p,+16, which are consistent with pRCC karyotyping. B, virtual karyotyping of the UOK146 cell line shows 3p loss, 9 p loss, 17 p loss and 17 gain. C, conventional karyotyping of the UOK146 cell line shows the following alterations: M1 = del(1p), M2 = del(3p), M3 = del(6q), M4 = i(17q), and M5 = t(X;1)(p11.2;q21.2). D, FISH result for TFE3 split in the novel MDA-92 cell line.
Supplementary Figure 2 from Ontogeny and Sorafenib Metabolism
Authors: Zimmerman Eric I. , Roberts Justin L. , Li Lie , Finkelstein David , Gibson Alice , Chaudhry Amarjit S. , Schuetz Erin G. , Rubnitz Jeffrey E. , Inaba Hiroto , Baker Sharyn D.
Published: April 2023

PDF file, 65K, Sorafenib metabolism by CYP and UGT enzymes.
Supplementary Table 4 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Authors: Dunbier Anita K. , Ghazoui Zara , Anderson Helen , Salter Janine , Nerurkar Ashutosh , Osin Peter , A'hern Roger , Miller William R. , Smith Ian E. , Dowsett Mitch
Published: April 2023

PDF file - 68K, Multivariable analysis of inflammatory metagene, grade, ER H-score, baseline Ki67 and proportional change in Ki67.
Supplementary Figure 6 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
Authors: Moschetta Michele , Basile Antonio , Ferrucci Arianna , Frassanito Maria Antonia , Rao Luigia , Ria Roberto , Solimando Antonio Giovanni , Giuliani Nicola , Boccarelli Angelina , Fumarola Fabio , Coluccia Mauro , Rossini Bernardo , Ruggieri Simona , Nico Beatrice , Maiorano Eugenio , Ribatti Domenico , Roccaro Aldo M. , Vacca Angelo
Published: April 2023

PDF file, 97K, SU11274 impacts marginally on in vivo growth of RPMI8226 plasmocytomas. It reverts bortezomib-resistance in R5 plasmocytomas.
Supplementary Figure 3 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
Authors: Moschetta Michele , Basile Antonio , Ferrucci Arianna , Frassanito Maria Antonia , Rao Luigia , Ria Roberto , Solimando Antonio Giovanni , Giuliani Nicola , Boccarelli Angelina , Fumarola Fabio , Coluccia Mauro , Rossini Bernardo , Ruggieri Simona , Nico Beatrice , Maiorano Eugenio , Ribatti Domenico , Roccaro Aldo M. , Vacca Angelo
Published: April 2023

PDF file, 121K, SU11274 inhibits p-cMET expression and chemotaxis toward fibroblasts' conditioned medium more intensely in R5 cells.
Supplementary Table 5 from Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma
Authors: Wei Rongrong , Huang Guo-Liang , Zhang Mei-Yin , Li Bin-Kui , Zhang Hui-Zhong , Shi Ming , Chen Xiao-Qian , Huang Long , Zhou Qing-Ming , Jia Wei-Hua , Zheng X.F. Steven , Yuan Yun-Fei , Wang Hui-Yun
Published: April 2023

PDF file, 148K, Univariate and multivariate analysis of features associated with overall survival in the test and independent sets (n = 106).
Supplementary Figure 1 from Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma
Authors: Wei Rongrong , Huang Guo-Liang , Zhang Mei-Yin , Li Bin-Kui , Zhang Hui-Zhong , Shi Ming , Chen Xiao-Qian , Huang Long , Zhou Qing-Ming , Jia Wei-Hua , Zheng X.F. Steven , Yuan Yun-Fei , Wang Hui-Yun
Published: April 2023

PDF file, 220K, Classification and Prediction of HCC and NC samples by 30-miRNA signature.
Supplementary Tables 1 - 4 from Identification of Circulating MicroRNA Signatures for Breast Cancer Detection
Authors: Chan Maurice , Liaw Chiew Suan , Ji Shen Mo , Tan Hwee Huang , Wong Chow Yin , Thike Aye Aye , Tan Puay Hoon , Ho Gay Hui , Lee Ann Siew-Gek
Published: April 2023

PDF file - 127K, Supplementary Table S1: Details of breast cancer patients employed for this study. IDC (NOS), Invasive Ductal Carcinoma (Not Otherwise Specified); DCIS, Ductal Carcinoma In-Situ; ILC, Invasive lobular carcinoma; LN, lymph node status; na, not available; nd, not detected. Supplementary Table S2: Complete list of significant microRNAs identified from breast cancer tumour and serum samples. Supplementary Table S3: Complete list of significant breast cancer tumour microRNAs associated with clinicopathological features. Supplementary Table S4: Complete list of significant serum microRNAs associated with clinicopathological features.
Supplementary Figure 8 from Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Authors: Mao Muling , Tian Feng , Mariadason John M. , Tsao Chun C. , Lemos Robert , Dayyani Farshid , Gopal Y.N. Vashisht , Jiang Zhi-Qin , Wistuba Ignacio I. , Tang Xi M. , Bornman William G. , Bollag Gideon , Mills Gordon B. , Powis Garth , Desai Jayesh , Gallick Gary E. , Davies Michael A. , Kopetz Scott
Published: April 2023

PDF file - 39K, HT29 PLX4720 resistant clone was treated with EGFR siRNA for 48 h, and then treated with 1�M PLX4720 for further two weeks. EGFR knockdown reduced sensitivity to PLX4720 by numbers of formed colonies (# P<0.01). The EGFR knockdown at 48h was shown by western blot.
Supplementary Figure 5 from MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation
Authors: Kim Won Kyu , Park Misun , Kim Young-Kook , Tae You Kwon , Yang Han-Kwang , Lee Jae Myun , Kim Hoguen
Published: April 2023

PDF file - 1.7MB
Supplementary Figure 4 from MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation
Authors: Kim Won Kyu , Park Misun , Kim Young-Kook , Tae You Kwon , Yang Han-Kwang , Lee Jae Myun , Kim Hoguen
Published: April 2023

PDF file - 1.8MB
Supplementary Table 1 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
Authors: Berlin Jordan , Bendell Johanna C. , Hart Lowell L. , Firdaus Irfan , Gore Ira , Hermann Robert C. , Mulcahy Mary F. , Zalupski Mark M. , Mackey Howard M. , Yauch Robert L. , Graham Richard A. , Bray Gordon L. , Low Jennifer A.
Published: April 2023

PDF file - 57K, A summary of primer/probes used for qRT-PCR profiling of Hh pathway genes
Supplementary Figure 3 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
Authors: Berlin Jordan , Bendell Johanna C. , Hart Lowell L. , Firdaus Irfan , Gore Ira , Hermann Robert C. , Mulcahy Mary F. , Zalupski Mark M. , Mackey Howard M. , Yauch Robert L. , Graham Richard A. , Bray Gordon L. , Low Jennifer A.
Published: April 2023

PDF file - 33K, Estimated maximal concentration (Cmax) and total area under the concentration-time curve (AUClast) of irinotecan (and metabolites SN-38 and SN-38G) with and without vismodegib
Supplementary Figure 1 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
Authors: Berlin Jordan , Bendell Johanna C. , Hart Lowell L. , Firdaus Irfan , Gore Ira , Hermann Robert C. , Mulcahy Mary F. , Zalupski Mark M. , Mackey Howard M. , Yauch Robert L. , Graham Richard A. , Bray Gordon L. , Low Jennifer A.
Published: April 2023

PDF file - 24K, A comparison of vismodegib steady-state plasma concentrations (Css) between patients receiving FOLFOX and FOLFIRI
Supplementary Table 2 from Integrative Array-Based Approach Identifies MZB1 as a Frequently Methylated Putative Tumor Suppressor in Hepatocellular Carcinoma
Authors: Matsumura Satoshi , Imoto Issei , Kozaki Ken-ichi , Matsui Takeshi , Muramatsu Tomoki , Furuta Mayuko , Tanaka Shinji , Sakamoto Michiie , Arii Shigeki , Inazawa Johji
Published: April 2023

PDF file, 60KB, Eleven candidates for epigenetically silenced genes in HCC cells identified through our integrated array-based approach.